Overall, ZNF638 is a biomarker of clinical response to ICI in GBM, suggesting that ZNF638 expression could not only predict clinical responses but may also serve as a target to potentiate immunotherapy across multiple tumor types. The gene discussed is ZNF638; the disease is neoplasm.